sofosbuvir/velpatasvir (Epclusa)

From Aaushi
Jump to navigation Jump to search

Indications

* for use in combination with ribavirin

* for patients both with & without cirrhosis

* FDA approved for use in children >= 6 years & 37 lbs mild or no cirrhosis

Dosage

Tablets: 400 mg sofosbuvir + 100 mg velpatasvir

Adverse effects

Drug interactions

More general terms

Components

References

  1. FDA News Release. June 28, 2016 FDA approves Epclusa for treatment of chronic Hepatitis C virus infection. First regimen to treat all six major HCV genotypes. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm508915.htm
  2. 2.0 2.1 FDA Drug Safety Communication: Oct 4, 2016 FDA warns about the risk of hepatitis B reactivating in some patients treated with direct-acting antivirals for hepatitis C. http://www.fda.gov/Drugs/DrugSafety/ucm522932.htm
  3. 3.0 3.1 3.2 Mucke MM, Backus LI, Mucke VT et al Hepatitis B virus reactivation during direct-acting antiviral therapy for hepatitis C: a systematic review and meta-analysis. Lancet Gastroenterology & Hepatology. Jan 19, 2018 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/29371017 <Internet> http://www.thelancet.com/journals/langas/article/PIIS2468-1253(18)30002-5/fulltext
  4. FDA Press Release. March 19, 20202 FDA Approves New Treatment for Pediatric Patients with Any Strain of Hepatitis C. https://www.fda.gov/news-events/press-announcements/fda-approves-new-treatment-pediatric-patients-any-strain-hepatitis-c
  5. 5.0 5.1 HIGHLIGHTS OF PRESCRIBING INFORMATION EPCLUSA.EPCLUSA (sofosbuvir and velpatasvir) tablets https://www.gilead.com/-/media/files/pdfs/medicines/liver-disease/epclusa/epclusa_pi.pdf